Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 AM Pacific Time in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved for the
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]Yahoo! Finance
- Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.MarketBeat
- Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
- Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- CYTK's page on the SEC website